Senores Pharmaceuticals plans ₹43 crore capacity expansion at subsidiaries

Guidance
pharmaceuticals

Blacklitt Research29 October 20262 min read

Senores Pharmaceuticals (NSE: SENORES) said in a filing on 29 Oct 2026 that its subsidiaries have planned capacity expansions estimated at ₹43 crore in total, covering Havix Group and Apnar Pharma and a new prefilled syringe line at Ratnatris Pharmaceuticals. The company said the expansions are likely to be completed by end of March 2027.

Key highlights

,Havix Group: capacity from 1.2 Bn to 2.0 Bn units per annum, estimated cost ₹18.00 crore
Apnar Pharma: capacity from 0.5 Bn to 1.2 Bn units per annum, estimated cost ₹20.00 crore
Ratnatris: new prefilled syringe line of 2.7 Mn units per annum, estimated cost ₹5.00 crore
Completion expected by end of March 2027

The capacity expansions in numbers

Item	Detail
Havix Group, USA	Capacity 1.2 Bn to 2.0 Bn units per annum; estimated cost ₹18.00 crore
Apnar Pharma Private Limited, India	Capacity 0.5 Bn to 1.2 Bn units per annum; estimated cost ₹20.00 crore
Ratnatris Pharmaceuticals Private Limited	New prefilled syringe line, 2.7 Mn units per annum; estimated cost ₹5.00 crore
Completion	By end of March 2027
Funding	Internal accruals and IPO proceeds, per Annexure A

Scale and timing of the expansions

Havix Group's proposed addition is 0.8 Bn units and Apnar Pharma's is 0.7 Bn units, per annum. The company's filing says Havix Group's existing capacity utilisation is approximately 50-70%.

The filing says the rationale is to meet existing and future demand.

Funding and the cost of the plan

Annexure A says the capacity expansions will be financed through internal accruals and IPO proceeds. The filing does not give the split between the two sources.

Together the three estimated costs come to ₹43 crore. Against Senores' market value of ₹6,098 crore, that is about 0.7%.

What the capacity expansions mean for Senores Pharmaceuticals' shareholders

The expansions add capacity at subsidiaries, with estimated costs of ₹43 crore in total. The company says the rationale is to meet existing and future demand.

The filing does not say what revenue or earnings impact the expansions will have, how much of the funding comes from each source, or whether the company will fund costs beyond the stated amounts. The next dated step is completion by end of March 2027.

Reference: Original filing (PDF)

Sign up to continue reading

Create a free account to read the rest of this article and the analysis that follows.

Disclaimer:

The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.